Exelixis | EXEL - Ebitda



金融业
股票价格
USD
资产
USD 2.49B
现金及等价物
USD 281.45M
销售成本
USD 20.66M
流动资产
USD 1.25B
流动负债
USD 361.93M
债务
USD 165.93M
EBIT
USD 248.41M
EBITDA
USD 255.4M
员工
1.15K
EPS每股收益
USD 0.91
股本和储备
USD 1.84B
销售毛利
USD 608.03M
债务利息支出
USD 23.4M
利息收入
USD 14.21M
市值
USD 14.53B
净收入
USD 212.05M
营业费用
USD 380.28M
营业利润
USD 248.41M
普通股股本
USD 248.89M
PE价格收益
18.02
税前利润
USD 262.68M
销售收入
USD 628.69M
销售和管理费用
USD 147.63M
股票
USD 28.73M
贸易债权人
USD 39.06M
应收帐款人
USD 322.21M


Ebitda 更改 日
Acadia Pharmaceuticals USD -1.62M 21.94M 2026-03
Agios Pharmaceuticals USD -108.66M 11.65M 2026-03
Akebia Therapeutics USD 14.03M 17.19M 2025-03
Amgen USD 3.86B 1.28B 2026-03
AstraZeneca USD 5.16B 510M 2026-06
Bayer EUR 2.14B 2.31B 2026-06
BioMarin Pharmaceutical USD 146.05M 170.22M 2026-03
Bristol-Myers Squibb USD 4.24B 1.37B 2026-03
Cytokinetics USD -169.32M 19.48M 2026-03
Eisai JPY 34.15B 34.48B 2026-06
Eli Lilly USD 10.29B 1.86B 2026-03
Exelixis USD 255.4M 2.89M 2026-06
Genmab DKK 401M 186M 2026-06
Glaxosmithkline GBP 2.77B 1.98B 2026-03
Incyte USD 778.57M 410.6M 2026-06
Ionis Pharmaceuticals USD -64.53M 135.49M 2026-03
MacroGenics USD -30.2M 52.15M 2026-03
Merck USD -1.54B 7.84B 2026-03
Moderna USD -1.26B 468M 2026-03
Nektar Therapeutics USD -38.9M 7.09M 2026-03
Neurocrine Biosciences USD 193.3M 25.1M 2026-03
Novartis USD 6.48B 1.19B 2026-06
Pfizer USD 6.01B 18M 2026-06
Puma Biotechnology USD 729K 11.36M 2024-06
Sanofi EUR 2.72B 2.94B 2026-03
Takeda JPY 364.46B 214.21B 2026-06
Ultragenyx Pharmaceutical USD -155M 55.57M 2026-03
Xencor USD -34.63M 86.74M 2026-06